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Papanicolaou testAbstract Organised screening programmes have been remarkably successful in reducing
incidence and mortality from cervical cancer, while opportunistic screening varies in its
effectiveness. Experts recommend that cervical screening or HPV testing be carried out only
in the context of an organised programme. We sought to answer the following study
questions: What does it mean for a cervical screening programme to be organised? Is there
a place for opportunistic screening (in an organised programme)? We reviewed 154
peer-reviewed papers on organised and opportunistic approaches to cervical screening
published between 1970 and 2014 to understand how the term ‘organised’ is used, formally
and in practice. We found that despite broad recognition of a prescriptive deﬁnition of orga-
nisation, in practice the meaning of organisation is much less clear. Our review revealed
descriptions of organised programmes that differ signiﬁcantly from prescribed norms and
from each other, and a variety of ways that opportunistic and organised programmes
intersect. We describe the breadth of the variation in cervical cancer screening programmes
and examine the relationships and overlaps between organised and opportunistic screening.
Implications emerging from the review include the need to better understand the breadth of
organisation in practice, the drivers and impacts of opportunistic screening and the impact
of opportunistic screening on population programme outcomes. Appreciation of the complex-
ity of cervical screening programmes will beneﬁt both screeners and women as programmes
are changed to reﬂect a partially vaccinated population, new evidence and new technologies.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).032963.
.edu.au
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Cervical screening has a long history in most well-
resourced countries around the world. Many countries
have commenced with ad hoc screening oﬀered and
taken up by a few, followed by a wider policy of pro-
moting opportunistic screening, and eventually by the
development and implementation of a national or regio-
nal ‘organised’ screening programme [1–5]. It is widely
held that organised programmes are more eﬀective than
non-organised, or opportunistic, screening programmes
in preventing cervical cancer, and it is well recognised
that organised cervical screening reduces cervical cancer
incidence and mortality [6–15].
Early observational studies compared diﬀerent
populations by screening activity [8,14,16–18]. Most of
these studies compared screened populations in Iceland
or Finland, where national programmes have been
organised since 1963–4, with similar populations in
locations where screening was organised later or not
organised. Nordic studies continued into the 1990s and
provide a strong evidence base about the forms of
organised screening that were adopted in those countries
[19,20]. The evidence particularly suggests that this kind
of organisation maximises the proportion of the popula-
tion screened, and shows that the more women screened
(as diﬀerentiated from the more tests done), the lessSearch Results:
Review by tle and abst
Review full text: 593
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Detail:
Meeng outcomes & guidelines = 17
Editorial = 4
Characteriscs of organisaon = 23
Opportunisc programs (descripon
with organised) = 29
Descripons of organised programs 
Evidence for organisaon = 15
Included:
Addional from bibliographies, 
snowballing
Policy recommendaons by 
internaonal bodies
= 30
Databases:
Medline = 765
Web of Science = 866
Fig. 1. Searching andmorbidity and mortality from cervical cancer [4,7,11,
20–22]. In contrast, opportunistic screening is often
characterised by the over-screening of a minority of
women, while those women most at risk tend to be
screened rarely or not at all [6,11,23,24].
Organised screening is often deﬁned in opposition to
widespread opportunistic or ad hoc screening. We will
argue that this dichotomisation of organised and oppor-
tunistic cervical cancer screening is more theoretical
than practical and does not reﬂect actual policy and
practice. A review of the literature revealed that, while
prescriptive deﬁnitions of ‘organisation’ are widely
recognised, in practice organised programmes diﬀer
signiﬁcantly from prescribed norms and from each
other, and opportunistic and organised programmes
intersect in a variety of ways. In this paper we describe
the breadth of the variation in cervical cancer screening
programmes and examine the relationships and overlaps
between organised and opportunistic screening.2. Methods
We sought to answer the following study questions
1. What does it mean for a cervical screening
programme to be organised? 1631
Excluded: 310
Duplicates
Leers
Conference abstracts
ract: 1321
Excluded: 728
Screening unrelated to cervix
Non-English full text
Earlier iteraon of same paper
Natural history / HPV and non-screening
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Epidemiology only
Technical (test) only
Insuﬃcient focus on organised or opportunisc 
screening
 or as a comparison 
= 66 
selection process.
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organised programme)?
We searched Medline and Web of Science for peer-
reviewed papers from 1970 until 1st April 2014, restricted
to English language papers. The Medline search was:
[[Uterine Cervical Neoplasms (MESH) OR pap* OR
smear* OR Pap* test*] AND [opportunistic OR organ-
ised OR organised] AND [Mass screening (MESH)]]
OR [Mass screening/og (organisation)(MESH) AND
Uterine Cervical Neoplasms (MESH)]. This search
returned 765 results. The Web of Science search string
was: [Cervical screening] AND [organis* OR organiz*],
which yielded 866 results.
We combined the searches and excluded duplicate
papers, letters, conference abstracts and those that did
not contribute to answering the review questions. 124
papers remained. We then conducted a hand search of
bibliographies and for outputs of international meetings
that generated screening guidelines, which led to an
extra 30 papers being included in the ﬁnal count. The
total number of papers included in the review was 154.
Paper selection is summarised in Fig. 1.
We identiﬁed a broad literature and included the fol-
lowing categories in our review: reports of meetings that
laid out prescriptions for optimal organisation; descrip-
tions of cervical screening programmes; evidence sup-
porting organised cervical screening; and papers
describing organised programmes and approaches to
opportunistic screening. Regarding the latter category:
because our aim was to determine the characteristics of
programmes described as ‘organised’, we did not apply
pre-determined deﬁnitions of ‘organised’ to determine
whether authors were ‘correctly’ or ‘incorrectly’ referring
to a programme as organised. Rather, we examined
descriptions of programmes, so as to determine how
the label ‘organised’ was being used in practice.
3. Results
We found that although, in principle, there is a shared
formal deﬁnition of what constitutes an organised pro-
gramme, the practice of organised cervical screening is
wide-ranging and complex. There is signiﬁcant variation
in how programmes are organised between and within
countries and regions. Our review revealed that in all
jurisdictions with organised screening programmes, at
least some and often a great deal of opportunistic screen-
ing is also undertaken, and data from that opportunistic
screening are often not captured. The way opportunistic
and organised screening intersect varies and the impact
of one on the other is uncertain.
3.1. There are formal criteria for the organisation of
cervical screening
European guidelines recommend that cervical screening
should happen only in the context of an organisedprogramme [25–27]. In the mid-1980s, regional European
cancer bodies outlined what was needed institutionally
andoperationally for aNordic-style organised programme
to be put in place and deﬁned the elements that made a
programme ‘organised’ [4,6,9,28,29]. Formal European
guidelines for cervical screening organisation were
produced in 1993 [30] and comprehensively updated in
2008 [25,31–33]. Recent guidelines remain strongly based
on those ﬁrst developed in 1984, paraphrased in Box 1
[4,33].Box 1 Guidelines for organising.
1. The target population has been identiﬁed – there
is policy on ages for starting and stopping
screening, screening intervals, and screening
post-hysterectomy;
2. Individuals are identiﬁable via a population-
based register;
3. Recruitment measures are available to guarantee
high coverage, for example recruitment via
personal invitation;
4. Adequate facilities exist for taking and reading
smears;
5. Quality control exists for the taking and reading
of smears;
6. Adequate facilities exist for diagnosis and
treatment of conﬁrmed neoplastic lesions;
7. An established screening pathway exists; and
8. Epidemiological monitoring and evaluation can
compare incidence and mortality in screened
and unscreened populations at the level of the
total target population, and data are controlled
for quality.
Further guidelines exist, some with added focus on
the need for assigning central responsibility and others
on data collection [6,23,30,34–38].3.2. Deﬁnitions of organisation usually hinge on the
existence of a population register
While there are comprehensive prescriptive guide-
lines, and many papers that describe ‘our organised
programme’, few authors have explicitly sought to deﬁne
the diﬀerence between ‘organised’ and ‘non-organised’
programmes. Often, ‘programme’ is used without a sig-
nal to the reader as to its status. When authors do seek
to diﬀerentiate, statements like these are typical:
‘Organised screening is distinguished from unsystematic
screening primarily on the basis of how the oﬀer of
screening occurs –whether by invitation, issued from
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or ‘organised screening is distinguished from opportunis-
tic screening primarily on the basis of how invitations to
screening are extended [40].’ That is, in the literature,
consideration of whether or not a programme is organ-
ised tends to come down to one key factor: whether or
not all eligible women are personally invited to attend
screening [5,39–43]. This aspect of organisation relies
on the existence and availability of a population register
to a screening programme.3.3. Descriptions of organised programmes show diversity
and inconsistency in practice
Thus far we have focused on the abstracted, or ideal,
conception of screening organisation. We now turn to
organisation in practice. Table 1 outlines the variation
that exists within organised screening programmes inter-
nationally. Many full descriptions of cervical screening
programmes have been published, particularly regarding
programmes operating in Europe, and such accounts
serve to highlight the diﬀerences in organised pro-
gramme guidelines and operations [2,5,44–66]. In prac-
tice there is considerable variation in how programmes
are organised [67,68] and how the deﬁning label of
organised is used. Note that this variability can attract
censure: screening programmes within the EU that are
inconsistent with IARC (2005) evidence-based recom-
mendations are often criticised in the literature
[13,26,69].
Organised programmes outside the EU are similarly
diverse. In South Korea, for example, there is no upper
age limit for screening and two diﬀerent sets of recom-
mendations are in place [59,70]. Australia’s and New
Zealand’s organised programmes do not invite eligible
women for screening and instead have a reminder
system that calls only previously screened women who
are overdue for a Pap test. Organised screening in
Singapore captures data only from women being
screened in government facilities [3].
Screening may be organised inconsistently across and
within countries and regions. Examples of diﬀerent
programmes operating within one country can be seen
in France, Italy, Greece, Belgium, Spain, Canada and
Thailand, where some provinces or local government
areas have population-based public health screening
programmes while others rely on opportunistic
screening [5,50,52,60,71–74]. Populations also have
diﬀerent access to organised programmes based on
factors other than geography. The United States, for
example, has organised and funded cervical screening
programmes in most states for eligible underserved
women [75–77]. Conversely, some organised screening
programmes may not be available to women who
cannot pay to attend.3.4. Multiple relationships exist between organised and
opportunistic screening
Organised screening is often deﬁned in terms of what
it is not, that is, an organised screening programme is
not opportunistic or unorganised. In reality they are
often both occurring and are likely to be complemen-
tary. Our close reading of the literature suggests a more
complex relationship than the either/or scenario usually
implied by guidelines and recommendations.
What is deﬁned as an opportunistic test depends on
the way a programme is run. There is no self-evident dis-
tinction between opportunistic and organised tests: this
distinction requires a decision regarding how the border
between programme and non-programme smears will be
deﬁned. In a programme with personalised invitations,
an opportunistic test might be classed as one that is
oﬀered or requested without an invitation. In pro-
grammes without invitations, it might be a test oﬀered
in a general practice (family physician) consultation out-
side of normal screening intervals or in the emergency
department of a hospital. While some registers have
the capacity to record the reason for smears taken
[78], most do not. This means that data on the total
number of smears will usually include diagnostic and
follow-up tests as well as screening tests. Levels of
opportunistic testing as a proportion of overall testing
are therefore diﬃcult to gauge. Estimates of rates of
opportunistic testing may be gained from surveys or
questionnaires [79,80], extrapolated from the total num-
ber of Pap tests paid for by insurance schemes [78,81], or
from the number of women rescreening early [82]. Box 2
Summarises the ways opportunistic screening was
described in relation to organised programmes in the
literature.Box 2 How opportunistic screening occurs.
 Alongside organised screening, particularly in
women at higher risk (in clinics and hospitals)
and lower risk (via privately funded gynaecologists)
 In the absence of organised screening, with varied
eﬀectiveness
 After an organised programme has been discon-
tinued, often with suboptimal results
 As a quasi-organised programme, where some
elements of organisation are adopted
Opportunistic screening occurs alongside organised in
all the EU member states that have organised pro-
grammes to a greater or lesser degree [13,42]. For
Table 1
Variations in organised screening programmes.a
Established criteria for organised
programmes [4,33]
Variation observed across existing programmes
Deﬁned target population (based
on risk)
There was wide variation in the included population:
 Large variation in starting age (15 [55]–30 [78]) [35] and stopping age (60-no speciﬁed upper age
[55,59])
 Screening intervals vary from 1 to 5 years [55,102]
Register of individual While guidelines emphasise the importance of a population-based register, organised programmes relied
on a wide range of systems for identifying eligible individuals:
 National population registers [44]
 GP registers [1,53]
 State/local government registers [71]
 Screened women registers [40,82]
 (National) health insurance lists [40,50]
 Combination of GP and insurance register [49]
Recruitment Recruitment systems in use:
 Invitation from a central register (with or without pre-set appointment) [44,53]
 No population register, reminder to ‘late’ previously screened women [82]
 Invitation from GP at the discretion of individual practices [42]
 Many programmes also have mass media and awareness campaigns
Facilities for taking and reading
smears
Methods of testing varied widely:
 Smear takers included: GPs [53]/Nurses [53,96]/Midwives [44]/Obstetricians and gynaecolo-
gists [2,42,45]
 Screening tests included: Pap test using conventional cytology or liquid based cytology [42];
HPV test (alone or in conjunction with Pap test) [67]; colposcopy [71]; VIA [62,90]
Quality control The majority of descriptions did not include details of quality control, though guideline based quality
assurance is widely reported [67]
Facilities/recommendations for
abnormalities
Criteria and method used for follow up of abnormal test results were not often detailed in programme
description. The variation that was described included:
 HSIL to colposcopy [44]
 HPV 16/18 to colposcopy [101]
 LSIL to colposcopy [60,95]
 LSIL to HPV test (in older women) [1,95]
 LSIL to repeat cytology in 6 mo/12 mo/24 mo [95]
 VIA-detected abnormality to colposcopy or cryotherapy[90]
Integrated screening pathway Little mention of this aspect of organisation in the organising literature
Epidemiological monitoring Little mention of this aspect of organisation in the organising literature
a Programmes were included if they were referred to as organised in the literature. Some descriptions were of national cervical screening
programmes that varied between regions. Where one or more regions had an organised screening programme it was included in the table. Note that
this table is not exhaustive and indicates only the variation found rather than the inclusion of all screening programmes in the literature. Many
programme descriptions do not include all aspects of the criteria recommended by/for EU cervical screening.
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forms the basis for much of the evidence about organi-
sation [35]. It has one of the most successful and least
intensive screening programmes in the world. However
high levels of opportunistic screening occur outside of
the programme, generally estimated at around twice
the number of programme-generated screening tests
[44,79]. High levels of opportunistic testing also occur
alongside the organised programme in Sweden, whereas
they are considerably lower in the Netherlands and the
United Kingdom (UK) [78]. The inﬂuence of opportu-
nistic testing on programme outcomes is unclear.
Opportunistic screening of higher risk women occurs in
the context of some organised programmes and there
is evidence in the literature to support this practice.
Examples include oﬀering Pap tests at STI clinics, at
genitourinary departments in hospitals, at EDs, and in
prisons, all of which are described as more likely to
reach un- or under-screened women [83–87]. The US
has organised programmes solely for higher risk women[76]. There are also examples of lower risk women being
opportunistically screened in addition to or instead of
screening prompted by invitation. Some wish (or are
encouraged) to be tested more frequently or outside of
the age ranges the programme’s screening interval dic-
tates [86,88]. Opportunistic screening of normal or low
risk women covered by organised programmes tends
to be carried out by gynaecologists [71] and may be rou-
tine or sporadic [88]. Some programmes discourage
excess testing in low risk women in recognition of the
increased harms of non-indicated testing and the unnec-
essary use of resources. In these cases, diversion away
from excess opportunistic testing takes the form of
restricting reimbursement [78]. Conversely, some pro-
grammes use reimbursement schemes that encourage
adherence to programme guidelines [42,53,82].
A minority of countries or regions with opportunistic
screening only achieve good outcomes in mortality
reduction from cervical cancer. Germany’s programme,
not organised and widely criticised for over screening
3034 J.H. Williams et al. / European Journal of Cancer 50 (2014) 3029–3038[13,69], has resulted in a strong decline of incidence and
mortality since the 1960s [81]. The United States and
some Canadian provinces show that it is possible to
achieve very wide population coverage [5,80] without
an organised screening programme in place, albeit at
the expense of higher resource use and potential over
screening [31]. US cervical screening levels are estimated
to be among the highest of any country, including the
screening of women with income below the poverty
threshold [40,76,80].
Organised and opportunistic screening may also hap-
pen in the same jurisdiction sequentially. Most commonly,
an organised programme follows years of opportunistic
screening but sometimes an organised programme is
halted and opportunistic screening encouraged in its place
[2,43,89]. In this case, a high uptake of screening in a
population programme does not necessarily translate to
high uptake of opportunistic screening. For example,
stopping organised screening in a county in Denmark
did not see continued high levels of screening under an
opportunistic model [43]. Similarly, a study in Australia
showed that screening rates in remote Aboriginal
communities were very high while a visible and active
organised programme was in place, but dropped
dramatically when the intervention ﬁnished [89].
Healthcare reforms in Bulgaria saw the dismantling of
an existing National Cervical Screening Programme in
that country; subsequent adoption of opportunistic
screening has been low and cervical cancer incidence
has risen [2]. That is, in those situations the beneﬁts
accrued by organised screening were not sustained and
the opportunistic screening that followed showed the
suboptimal results that are generally expected of unor-
ganised approaches.
Some programmes are described as opportunistic
with ‘aspects of organisation’ [90], or call for ‘more
organised opportunistic screening’ [91]. This may be in
part a response to the need to maximise limited
resources for cervical screening. Such cases highlight
the fact that (a) the word ‘organised’ has a common
language use that may be employed in place of or in
addition to its technical use and (b) professional under-
standings of ‘opportunistic’ and ‘organised’ screening
may not be as dichotomous as is suggested by
guidelines.3.5. It is not clear how co-existing opportunistic and
organised screening aﬀect each other
Data on screening tend to be routinely captured for
organised programmes only, making it diﬃcult to assess
any contribution that opportunistic screening makes to
overall cervical cancer mortality beneﬁt. As well as con-
tributing to beneﬁt however, opportunistic screening
may also detract from population-wide programmes.
A description of cervical screening in Hong, Kong,Singapore and Taiwan suggests that high levels of
opportunistic screening in those countries are detrimen-
tal to participation in the organised programmes that
operate. Uptake of organised screening is low, and
opportunistic data are not captured [3]. However screen-
ing levels generally are high and incidence of cervical
cancer comparatively low in these countries [92].4. Discussion
This review indicates that there is signiﬁcant variation
in the organisation and delivery of cervical screening
programmes despite consistency in what is considered
organised. This practice-based inconsistency is not neces-
sarily problematic (in fact it seems an inevitable response
to diverse health systems). However, using a single label
to describe programs that may have little in common
obscures diﬀerence and could perpetuate a narrow
understanding of how screening programmes may
optimally operate within the conﬁnes of each jurisdic-
tion. Since the publication of early studies in support
of cervical screening, the literature continues to be heav-
ily dominated by European evidence and programme
description. In 2003, a unanimously adopted European
Union recommendation promised equal access to
organised cervical screening for all women in the cervical
screening target population in all EU member states
[93,94] making a considerable variation in policy,
practice and process performance [95] within the region
all the more notable. As the most recent IARC survey
highlighted, a large number of women in Europe and
beyond do not have access to free Pap testing under
any type of programme, including some that are
organised [2,35,96].
This variability seems unlikely to change, however.
Existing healthcare systems and competing healthcare
priorities, particularly in some newer member states, sug-
gest a uniform EU-wide approach to cervical screening is
improbable. Furthermore, a Finnish-style prescription
for screening is unlikely to be adopted in even
well-resourced countries with philosophically diﬀerent
approaches to healthcare such as the United States.
Arguments for organisation per se in that context are
given much less weight than those of resource allocation
[39,97]. Attempts by some LMIC countries to organise
screening have not shown any mortality beneﬁt; others
have [98]. Attitudes towards privacy vary and determine
the political feasibility of the use of population registers
in some screening programmes. The evidence and guide-
lines generated by the Nordic countries may not there-
fore be transferable to countries with diﬀering resource
limitations, health systems, underlying political philoso-
phies, societal norms and values [91], or very diﬀerent
underlying levels of risk [64,91].
Some aspects of organisation did not feature in the
literature with any consistency. Anecdotally, funding
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erably, from both visit and test being free to women, to
cytology only being subsidised, to women being respon-
sible for payment for both smear taking and cytology.
Discussion of funding arrangements for screening,
whether opportunistic or organised, was seldom
included in the organising literature however. Some
funding arrangements may be a barrier to population-
wide access. Similarly, the organisational literature did
not focus on programme approaches to communication
with women. Maximising participation is key to a utili-
tarian approach to screening, where evidence of beneﬁt
is based on incidence and mortality rates of cervical can-
cer in a population. Diﬀerent sub-populations have dif-
ferent levels of risk, however, and a one-size-ﬁts-all
approach to communicating risk may not always be
appropriate. This heterogeneity and its implications
for ethical communication are outlined in the EU rec-
ommendations [99,100] and the literature may soon
begin to reﬂect updated approaches accordingly.
Finally, the descriptions of cervical screening we ana-
lysed largely focused on the initial screening encounter.
Screening programmes should however include not just
an initial test but everything that might conceivably
result from that test, including follow-up tests and any
required treatment [35], and ethical arguments can be
made that a screening programme must ensure access
to all aspects of the screening pathway and not just
the existence of test facilities [24,35]. Finland, with its
model programme, explicitly includes all follow up and
treatment within its funding model as do other countries
with similar healthcare systems [2]. However most
descriptions of screening for cervical cancer do not
include details of how diagnosis or treatment is organ-
ised, accessed or paid for, which has limited our ability
to consider this issue.
There are several implications that emerge from this
review:
1. The high level of opportunistic screening that occurs
in many jurisdictions with organised programmes
needs to be better appreciated and understood. It
may indicate, for example, that some aspects of orga-
nisation (such as screening interval) may not be
acceptable to women or practitioners; that communi-
cation about the rationale for organised programmes
is insuﬃcient; or that practical aspects of the program
may not be meeting the needs of women or screeners.
2. The eﬀects of opportunistic screening on an organised
programme, and vice versa, need to be better under-
stood. It would be especially valuable to know the
extent to which opportunistic screening does or does
not contribute to low incidence and mortality in coun-
tries with eﬀective organised programmes with wide
population reach, such as those described in Finland,
the Netherlands and England. Many data sources donot have the capacity to distinguish between an in-
programme smear and one that is taken opportunisti-
cally. As programmes continue to develop in response
to new evidence or changing risk, adapting screening
registers to accommodate test reason would contrib-
ute to research into evidence of eﬀect.
3. An assumption of the homogeneity and exclusivity of
organised programmes is not accurate. Clearer
descriptions of what aspects of an organised pro-
gramme are speciﬁcally important in a given context
would allow readers to better interpret and apply
the ﬁndings of empirical research. This review shows
that it is not clear what it means for screening to hap-
pen only in the context of an organised programme,
given the variety that exists. This suggests that future
work on the ‘organisation’ of screening should be
explicit about the essential elements, goals and out-
comes of organisation. Organisation, for example,
may hinge on avoidance of over-testing by enforcing
strict screening intervals and target populations; alter-
natively, the goal of organisation may be to ensure
equity and maximise reach by inviting all eligible
women to participate. Until this is clariﬁed, the mean-
ing and signiﬁcance of ‘organisation’ will be
uncertain. Goals may diﬀer for diﬀerent programmes
and healthcare systems. Acknowledgement of
diﬀerence and description of what an organised
programme entails will help avoid inappropriate
comparison and assist policy makers to articulate
exactly what aspects of organisation are crucial to
their speciﬁc situations.
4. The vast bulk of the literature considered was
published before the advent of HPV vaccination. A
future challenge for the organisation of cervical
screening is to link it to this new context of eﬀorts to
vaccinate young people against HPV infection.
Because HPV vaccination is relatively new, the
current literature oﬀers little guidance about how this
can best be done: it remains an important question for
future research.
The literature in support of organised screening as
prescribed by European guidelines is compelling. As
new technologies for cervical and HPV screening are
introduced, the importance of limiting their use to
organised programmes has been stressed [101]. These
newer protections against cervical cancer will likely be
incorporated into existing and updated organised pro-
grammes. A homogeneous approach to organised
screening appears to be unrealistic in the short term.5. Recommendations
We draw on our review of the literature to make the
following recommendations:
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tion of speciﬁc programmes should be explicit about
the characteristics necessary to consider that popula-
tion programme ‘organised’, and should specify what
is not likely to be possible given resource constraints
or the parameters of existing healthcare systems.
 Similarly, recommendations for new technologies to
be used only within organised programmes should
be speciﬁc about how the technology needs to be
supported, by what kinds of organisation, and why.
 Further research into the relative beneﬁt of individual
elements of organised screening could assist with
decision making when programmes are being devel-
oped or adjusted.
A more detailed understanding of the complexity of
cervical screening programmes will beneﬁt both screen-
ers and women as programmes change to reﬂect a
partially vaccinated population, new evidence and new
technologies.Conﬂict of interest statement
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